Trials / Active Not Recruiting
Active Not RecruitingNCT05889988
A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
Conditions
Timeline
- Start date
- 2023-06-12
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2023-06-05
- Last updated
- 2025-11-20
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05889988. Inclusion in this directory is not an endorsement.